Philip Ginsburg, MD
Gastroenterology · Rutland, VTNPI 1679554539
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $446,491 of the $553,427 with a category attached, or 80.7%. 15 manufacturers reported payments, led by AbbVie at 39.9% of the total. Among gastroenterology clinicians in VT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $1229.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$221K
- Johnson & Johnson$146K
- Pfizer$75K
- Takeda Pharmaceuticals U.S.A., Inc.$49K
- E.r. Squibb & Sons, L.L.C.$29K
- Lilly USA, LLC$23K
- plus $12K from 9 others
Across 763 payments — averaging $3094.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.2M
- Pfizer$291K
- Takeda Pharmaceuticals U.S.A., Inc.$202K
- Janssen Research & Development, LLC$188K
- Eli Lilly$116K
- Genentech, Inc.$92K
- plus $305K from 10 others
What the payments were for
- Consulting fees$52,92510%
- Speaking & faculty fees$446,49181%
- Travel & lodging$42,3588%
- Food & beverage$11,5862%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 181 | $220,621 |
| Johnson & Johnson | 104 | $145,536 |
| Pfizer | 46 | $75,101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $48,874 |
| E.r. Squibb & Sons, L.L.C. | 21 | $28,787 |
| Lilly USA, LLC | 25 | $22,977 |
| Eli Lilly | 7 | $8,104 |
| Bristol Myers Squibb | 11 | $2,462 |
| Fresenius Kabi USA, LLC | 2 | $633 |
| Pentax Of America, Inc. | 9 | $132 |
| Medtronic | 1 | $69 |
| Digestive Care, Inc. | 2 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Shionogi Inc | 1 | $16 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$553,427 in reported general payments places this provider in the 95th percentile of 25 gastroenterology providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 63 | $1,816,223 |
| InflectraInfliximab-Dyyb | 21 | $145,129 |
| Xeljanz XrTofacitinib Citrate | 17 | $140,626 |
| Mesalamine | 93 | $83,030 |
| RinvoqUpadacitinib | 12 | $74,344 |
| PentasaMesalamine | 12 | $12,415 |
| Balsalazide Disodium | 16 | $2,967 |
| Colestipol Hcl | 16 | $2,416 |
| Mercaptopurine | 16 | $2,134 |
| CholestyramineCholestyramine (With Sugar) | 24 | $1,951 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 23 | $1,388 |
| LoperamideLoperamide Hcl | 13 | $1,014 |
| Desipramine Hcl | 23 | $903 |
| Esomeprazole Magnesium | 28 | $820 |
| Omeprazole | 50 | $629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $145,536 | $1,816,22363 claims |
| PfizerInflectra | $75,101 | $145,12921 claims |
| AbbVieRinvoq | $220,621 | $74,34412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 gastroenterology providers in Vermont.
Other gastroenterology in Rutland
- Joseph WilliamsRutland$0
- Michael GleesonRutland$0
- Peter MosesBurlington$8K
- Cory HalliburtonColchester$7K
- Heiko PohlWhite River Junction$5K
- David SchwartzColchester$3K
- David FurmanBennington$3K
- Michael UzerBurlington$2K
- Jason HeffleyBurlington$1K
- Ibrahim AbubakarBurlington$990
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.